



SIGACHI LABORATORIES LIMITED

Corporate Office: 411 , Raghava Ratna Towers,
Chirag Ali Lane, Hyderabad - 500 001. Telangana (INDIA)
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in
GSTIN: 36AACCS8220M1Z4 CIN: L24230TG1994PLC018786

Date: 29.05.2026

Head Listing & Compliance
Metropolitan Stock Exchange of India Limited
205(A), 2nd floor, Piramal Agastya Corporate Park,
Kamani Junction, LBS Road,
Kurla (West), Mumbai – 400070

Dear Sir,

Sub: Submission of Audited Financial Results along with segment results of the Company for the quarter and year ended 31-3-2026 along with the audit report - Reg.

Ref: Disclosure under Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- Reg.

Pursuant to Regulation 33 and Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors at its Meeting held today i.e., Friday, 29th May, 2026 had inter-alia considered and approved the following:

1. The Audited financial results for the quarter and year ended 31st March, 2026 along with Segment results, Statement of Assets and Liabilities and Cash Flow Statement as at 31.3.2026.
2. The Audited Financial statements for the Year ended 31st March, 2026.
3. Appointment of M/s. CRK & Associates, Chartered Accountants as Internal Auditors of the company for the year 2026-2027.
4. Purchase of Villa No.35, situated at S. No. 343/1, 343/2 and 338/2, Bidraguppe Village, Attibele Hobli, Anekal Taluk, Bangalore, Bangalore District for a consideration not exceeding Rs.1,20,00,000/- plus applicable stamp duty, GST and registration charges, for investment purposes.
5. Purchase of Plot Nos.20, 21 and 22, admeasuring area 167.00 Square Yards each situated in the HMDA approved layout named "HILL SIDE" at Maheshwaram Revenue Village and Gram panchayat, Maheshwaram Mandal, Ranga Reddy District, Telangana for a consideration not exceeding Rs.15 lakhs each plot plus applicable stamp duty and registration charges, from M/s. Amaze Infra Developers for investment purposes.



SIGACHI LABORATORIES LIMITED

Corporate Office: 411 Raghava Ratna Towers,
Chirag Ali Lane, Hyderabad - 500 001, Telangana (INDIA)
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in
GSTIN: 36AACCS8220M1Z4 CIN: L24230TG1994PLC018786

6. Purchase of Mahindra Electric car (XEV 9S Pack 3) for the company use at a price not exceeding Rs. 32,00,000/- (Rupees Thirty Two Lakhs only).

7. Approved the Loan Settlement proposal by Sri. B. Prasad, Director of SUPR Trade Links Private Limited.

Accordingly, please find enclosed herewith the following:

1. Statement of Audited Financial results for the quarter & year ended 31st March, 2026 along with the Segment results, Statement of Assets and Liabilities and Cash Flow Statement as at 31.3.2026.

2. Independent Auditor's Report on financial results for the quarter and year ended 31.3.2026, issued by M/s. NSVR & Associates LLP, Chartered Accountants Hyderabad, Statutory Auditors of the Company.

3. Declaration in respect of Audit Report with unmodified opinion for the financial Year ended on 31st March, 2026.

4. Statement of Deviation(s) or Variations(s) under Reg. 32 SEBI (LODR) Regulations, 2015.

5. Annexure I, II, III and IV as per applicable SEBI (LODR) Regulations, 2015 and SEBI Circular dated 11.11.2024.

6. Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding the One Time Loan Settlement (OTS) proposal by Sri. B. Prasad, Director of SUPR Trade Links Private Limited.

Further we wish to inform that following regulations are not applicable to our company:

a. Reg. 52(1) SEBI (LODR) Regulations, 2015 - We do not have any Debt Instruments.

b. Reg. 52(4) & 52(6) SEBI (LODR) Regulations, 2015 - We do not have any Non-convertible Instruments (Debt).

c. Reg. 54(2)/(3) SEBI (LODR) Regulations, 2015 - No security cover created as we do not have any Non-convertible Instruments (Debt).

The details required under Regulation 30 of the SEBI Listing Regulations, read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is enclosed as Annexure-I, II, III and IV.



SIGACHI LABORATORIES LIMITED

Corporate Office: 4th Raghava Ratna Towers,
Chirag All Lane, Hyderabad - 500 001, Telangana (INDIA)
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in
GSTIN: 36AACCS8220M1Z4 CIN: L24230TG1994PLC018786

Kindly take the above on your records.

Thanking you,

Yours faithfully,
For Sigachi Laboratories Limited

(Lekha Sai Surapaneni)
Company Secretary

The meeting Commenced at 4:00 PM
The Meeting Concluded at 9:00 PM

SIGACHI LABORATORIES LIMITED

Regd. Office: S.No: 530 & 534, Bonthapally - 502 313, Gummadidala Mandal, Sanga Reddy District, Telangana.

Tel No.: 040 - 23204230/23204273

Website:www.slllab.com, Email:sigachilaboratories@yahoo.co.in

CIN: L24230TG1994PLC018786

Statement of Audited Financial Results For the Quarter and Year Ended 31st March, 2026

(Rs. in Lakhs)

Sl.No.	Particulars	Quarter ended			Year ended	
		31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
	Income					
1	Revenue from operations	75.71	91.88	63.88	325.75	312.23
2	Other income	23.44	14.98	17.03	74.73	65.95
3	Total Income (1+2)	99.15	106.86	80.91	400.48	378.18
4	Expenses					
	a) Cost of materials consumed	-	-	-	-	-
	b) Changes in inventories	-	-	-	-	-
	c) Impairment on Advances	-	-	75.00	-	75.00
	d) Fair Value Losses	129.23	-	68.77	129.23	68.77
	e) Employee benefits expense	13.19	11.62	11.36	47.26	42.90
	f) Finance costs	0.22	0.07	-	0.29	-
	g) Depreciation and amortization expense	6.06	8.37	5.79	25.99	23.17
	h) Other expenses	4.79	5.16	5.47	16.81	16.12
	Total Expenses	153.49	25.22	166.39	219.58	225.96
5	Profit/(Loss) before exceptional items and tax (3-4)	(54.34)	81.64	(85.48)	180.90	152.22
6	Exceptional Items	-	-	-	-	-
7	Profit/(Loss) before tax (5-6)	(54.34)	81.64	(85.48)	180.90	152.22
8	Tax expense					
	(a) Current tax	18.35	13.24	14.28	54.52	45.61
	(b) Deferred tax	(18.00)	6.86	(9.49)	(7.59)	(12.49)
	Total Tax Expense	0.35	20.10	4.79	46.93	33.12
9	Profit/(Loss) for the Period (7-8)	(54.69)	61.54	(90.27)	133.97	119.10
10	Other Comprehensive income (OCI)					
	(a) Items that will not be reclassified to profit or (loss)	(293.57)	147.66	(172.02)	24.77	247.67
	(b) Remeasurement gains/(losses) on defined benefit plans	(0.14)	-	0.57	(0.14)	0.57
	(c) Tax on Items that will not be reclassified to (profit) or loss	(42.54)	27.77	24.50	(2.98)	(35.52)
	(d) Items that will be reclassified to profit or (loss)	-	-	-	-	-
	(e) Items that may be reclassified subsequently to profit or (loss)	-	-	-	-	-
	Total other Comprehensive income/(loss) for the period, net of tax	(251.17)	119.89	(146.95)	21.65	212.72
	Total Comprehensive income/(loss) (9+10)	(305.86)	181.43	(237.22)	155.62	331.82
11	Paid-up Equity Share Capital (Face Value of Rs.10/- each)	675.31	675.31	675.31	675.31	675.31
12	Other Equity	-	-	-	3,357.28	3,201.66
13	Earnings per equity share (of Rs.10/- each) (not annualized (in Rs.))					
	(1) Basic	(0.81)	0.91	(1.34)	1.98	1.76
	(2) Diluted	(0.81)	0.91	(1.34)	1.98	1.76

Segment wise Revenue, Results and Capital Employed For the Quarter and Year Ended 31st March, 2026

(Rs. in Lakhs)

Sl.No	Particulars	Quarter ended			Year ended	
		31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1	Segment Revenue					
	a) Bulk Drugs and Intermediates (Lease Rents)	52.00	39.00	48.00	155.00	140.50
	b) Investments	47.15	67.86	32.91	245.48	237.68
	Total	99.15	106.86	80.91	400.48	378.18
	Less: Inter Segment Revenue	-	-	-	-	-
	Net Sales/Income from Operations	99.15	106.86	80.91	400.48	378.18
2	Segment Results Profit/(Loss) before tax and finance costs from each segment					
	a) Bulk Drugs and Intermediates (Lease Rents)	45.23	30.45	42.03	127.40	115.42
	b) Investments	(82.08)	67.86	(35.86)	116.25	168.91
	Total	(36.85)	98.31	6.17	243.65	284.33
	Less: (i) Finance Costs	0.22	0.07	-	0.29	-
	(ii) Other Un-allocable Expenditure net off	17.27	16.60	91.65	62.46	132.11
	(iii) Un-allocable income	-	-	-	-	-
	Total Profit/(loss) Before Tax	(54.34)	81.64	(85.48)	180.90	152.22
3	Capital Employed					
	Segment Assets					
	a) Bulk Drugs and Intermediates (leased)	916.14	873.31	949.70	916.14	949.70
	b) Investments	3,350.03	3,752.96	3,141.63	3,350.03	3,141.63
	Total (A)	4,266.17	4,626.27	4,091.33	4,266.17	4,091.33
4	Segment Liabilities					
	a) Bulk Drugs and Intermediates (leased)	178.80	172.58	116.12	178.80	116.12
	b) Investments	(0.97)	59.49	42.49	(0.97)	42.49
	Total (B)	177.83	232.07	158.61	177.83	158.61
	Total (A-B)	4,088.34	4,394.20	3,932.72	4,088.34	3,932.72

Notes :

- The above statement of audited financial results of ("the Company"), which have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI") were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meeting(s) held on 29th May 2026. The Statutory Auditors have issued an unqualified report thereon.
- These Financial Results are available on the Stock Exchange website (www.msei.in) and also on the company's website at (www.sllab.com).
- The figures for the quarter ended 31st March, 2026 and 31st March, 2025 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published year to date figures upto the third quarter of the respective financial year(s) which were subjected to limited review.
- The figures for the previous periods have been rearranged/reclassified wherever necessary to conform to the current period presentation.

for SIGACHI LABORATORIES LIMITED

(T.R.Sekhar)

Executive Director

DIN:02943146

Place : Hyderabad

Date : 29.05.2026

SIGACHI LABORATORIES LIMITED
 Regd.Office: S.No: 530 & 534, Bonthapally - 502 313.
 Gummadidala Mandal, Sanga Reddy District, Telangana.
 Tel No.: 040 - 23204230 / 23204273
 Website:www.slllab.com, Email:sigachilaboratories@yahoo.co.in
 CIN:L24230TG1994PLC018786
 Statement of Assets and Liabilities as at 31st March, 2026

(Rs.in lakhs)

Particulars	As at 31.03.2026	As at 31.03.2025
	(Audited)	(Audited)
A. ASSETS		
1. Non-Current Assets		
(a) Property, Plant and Equipment	284.66	310.27
(b) Capital work in progress	202.53	-
(c) Right of Use Asset	9.25	-
(d) Financial Assets		
(i) Investments	3,144.68	2,967.63
(ii) Other Financial Assets	44.15	43.62
(e) Other non Current Assets	156.50	396.25
Total Non - Current Assets	3,841.77	3,717.77
2. Current Assets		
(a) Financial Assets		
(i) Investments	80.90	10.01
(ii) Trade Receivables	97.38	2.78
(iii) Cash and Cash Equivalents	33.48	186.48
(iv) Other Financial Assets	205.35	174.00
(b) Other Current Assets	7.29	0.29
Total Current Assets	424.40	373.56
Total Assets	4,266.17	4,091.33
B. EQUITY AND LIABILITIES		
1. Equity		
(a) Equity Share Capital	731.06	731.06
(b) Other Equity	3,357.28	3,201.66
Total Equity	4,088.34	3,932.72
2. Liabilities		
Non-Current Liabilities		
(a) Financial Liabilities		
(i) Lease Liabilities	9.44	-
(ii) Provisions	10.25	8.03
(iii) Deferred Tax Liabilities (net)	111.38	115.99
(iv) Other Non - Current Liabilities	35.00	25.00
Total Non - Current Liabilities	166.07	149.02
Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	-	-
(ii) Trade Payables		
(a) total outstanding dues of micro and small enterprises	-	-
(b) total outstanding dues of creditors other than micro and small enterprises	-	-
(iii) Other Financial Liabilities	9.23	9.04
(b) Other Current Liabilities	-	-
(c) Provisions	2.53	0.55
Total Current Liabilities	11.76	9.59
Total Equity and Liabilities	4,266.17	4,091.33

for SIGACHI LABORATORIES LIMITED

Place : Hyderabad
Date : 29.05.2026

(T.R.Sekhar)
Executive Director
DIN:02943146

Sigachi Laboratories Limited		
CASH FLOW STATEMENT FOR THE YEAR ENDED 31st March, 2026		
(Rs.in lakhs)		
Particulars	For the year Ended	
	31.03.2026 (Audited)	31.03.2025 (Audited)
Cash Flows from Operating Activities		
Net profit before tax	180.90	152.22
Adjustments for :		
Depreciation and amortization expense	25.99	23.17
Interest on lease liability	0.29	-
(Profit)/Loss on sale of Property, Plant and Equipment	(5.03)	-
Dividend Received	(54.53)	(50.75)
Provision for Gratuity & Leave Encashment	2.08	0.70
Provision for Impairment on Advances	-	75.00
Interest Received	(88.23)	(68.49)
Fair Value Losses	129.23	68.77
Fair Value (Gains)	(97.65)	(118.21)
Operating profit before working capital changes	93.05	82.41
Movements in Working Capital		
(Increase)/Decrease in Trade Receivables	(94.60)	17.43
(Increase)/Decrease in Other Financial Assets	(31.35)	(3.02)
(Increase)/Decrease in Other Current Assets	(7.00)	(0.18)
(Increase)/Decrease in Other Non Current Assets	239.75	(0.75)
Increase/(Decrease) in Other Current Financial Liabilities	0.19	2.97
Increase/(Decrease) in Other Non - Current Liabilities	10.00	-
Increase/(Decrease) in Provisions	1.98	(1.08)
(Increase)/Decrease in Other Non Current Financial Assets	(0.53)	-
Lease liability paid	(0.95)	-
Amortisation of Prepaid Lease	(0.03)	-
Changes in Working Capital	117.46	15.37
Cash generated from operations	210.51	97.78
Direct Taxes	54.52	45.61
Net Cash from operating activities (A)	155.99	52.17
Cash flows from Investing Activities		
(Purchase) of Property, Plant and Equipment	(204.23)	(11.84)
Sale of Property, Plant and Equipment	7.22	-
(Purchase) of Investments	(63.19)	(71.75)
Sale of Investments	0.11	40.64
Dividend Received	54.53	50.75
Interest Received	88.23	68.49
(Increase)/Decrease in other term deposits	(191.66)	13.49
Net Cash used in Investing Activities (B)	(308.99)	89.78
Cash flows from/(used in) Financing Activities		
Proceeds from Long term borrowings	-	-
Repayment/(Proceeds) of/from Short-term borrowings	-	-
Dividend Paid	-	-
Net Cash used in Financing Activities (C)	-	-
Net Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)	(153.00)	141.95
Cash and Cash Equivalents at the beginning of the year	186.48	44.53
Cash and Cash Equivalents at the ending of the year	33.48	186.48

for SIGACHI LABORATORIES LIMITED

Place : Hyderabad
Date : 29.05.2026

(T.R.Sekhar)
Executive Director
DIN:02943146

Independent Auditor's Report on the Quarterly and Year to Date Audited Standalone Financial Results of Sigachi Laboratories Limited ("the Company") pursuant to the requirements of Regulations 33 and 52 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015, as amended

To
The Board of Directors of
Sigachi Laboratories Limited

Report on the Audit of the Standalone Financial Results

Opinion

We have audited the accompanying statement of quarterly and year to date Standalone Financial Results of **Sigachi Laboratories Limited** (the "Company") for the quarter ended March 31st, 2026 and for the year ended March 31st, 2026 ("Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid annual financial results:

- Are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- Give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information for the year ended 31 March 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Annual Financial Results section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion on the annual financial results.



Management's Responsibilities for the Standalone Financial Results

These annual financial results have been prepared on the basis of the annual financial statements. The Company's Management and the Board of Directors are responsible for the preparation and presentation of these annual financial results that give a true and fair view of the net profit/ loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the annual financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.



- Conclude on the appropriateness of the management's use of the going concern basis of accounting and based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the Annual Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Financial Results may be influenced. We consider quantitative materiality and qualitative factors (i) in planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence and where applicable, related safeguards.

Other Matter

The Statement includes the results for the quarter ended March 31, 2026 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2026 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

Our opinion on the statement is not modified in respect of this matter.

For M/s. NSVR & ASSOCIATES LLP
Chartered accountants
FRN: 008801S/S2009960




V. Gangadhara Rao
Partner
Membership No: 219486
UDIN: 26219486QUIEKK6844

Place: Hyderabad
Date: 29-05-2026



SIGACHI LABORATORIES LIMITED

Corporate Office: 411 Raghava Ratna Towers,
Chirag Ali Lane, Hyderabad - 500 001, Telangana (INDIA)
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in
GSTIN: 36AACCS8220M1Z4 CIN: L24230TG1994PLC018786

Date: 29.05.2026

Head Listing & Compliance
Metropolitan Stock Exchange of India Limited
205(A), 2nd floor, Piramal Agastya Corporate Park,
Kamani Junction, LBS Road,
Kurla (West), Mumbai – 400070

Dear Sir,

Re: Declaration relating to the Unmodified Opinion by Statutory Auditors' on the Audited
Financial statements for the Quarter and Year ended 31st March, 2026 - Reg.

Pursuant to Regulation 33(3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to declare and confirm that the Statutory Auditors of the Company, M/s. NSVR & Associates LLP, Chartered Accountants (Firm Registration no. 008801S/S200060) have issued their Audit Report with unmodified opinion on the Audited Financial Results of the Company for the quarter and financial year ended 31st March, 2026.

This Declaration is issued in compliance of Regulation 33(3)(d) of the SEBI (LODR) Regulations, 2015 as amended vide its circular no CIR/CFD/CMD/56/2016 dated 27 May, 2016.

Please take the above declaration on record.

Thanking you,

Yours faithfully,
For Sigachi Laboratories Limited

(B. Kumar)
Chief Financial Officer



SIGACHI LABORATORIES LIMITED

Corporate Office: 411 Raghava Ratna Towers,
Chirag Ali Lane, Hyderabad - 500 001, Telangana (INDIA)
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in
GSTIN: 36AACCS8220M1Z4 CIN: L24230TG1994PLC018786

Date: 29.5.2026

Head Listing & Compliance
Metropolitan Stock Exchange of India Limited
205(A), 2nd floor, Piramal Agastya Corporate Park,
Kamani Junction, LBS Road,
Kurla (West), Mumbai – 400070

Dear Sir,

Sub: Non-Applicability of Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Reg.

Pursuant to the Regulation 32 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the company had made its public offer (Initial Public Offer IPO) near about 25 years back and the Company has fully utilized the proceeds of the IPO for the purpose for which the funds were raised. The company has not raised any fresh issue through public issue, rights issue, preferential issue, QIP, etc. Hence, the Statement of deviation(s) or variation(s) is not applicable to the Company

We request you to kindly take note of this information on your record and acknowledge.

Thanking you,

Yours faithfully,
For Sigachi Laboratories Limited

(Lekha Sai Surapaneni)
Company Secretary



SIGACHI LABORATORIES LIMITED

Corporate Office: 411 Raghava Ratna Towers,
Chirag Ali Lane, Hyderabad - 500 001, Telangana (INDIA)
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in
GSTIN: 36AACCS8220M1Z4 CIN: L24230TG1994PLC018786

Annexure-I

The Disclosure required under Regulation 30 of the SEBI Listing Regulations, read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024:

Appointment of M/s. CRK & Associates, Chartered Accountants, as Internal Auditors of the Company:

a.	reason for change viz. appointment, reappointment, resignation, removal, death or otherwise	M/s. Venkataratnam & Associates, Chartered Accountants, present internal auditors of the have not given their consent for reappointment. Based on the recommendation of the audit committee, the Board considered and approved the Appointment of M/s. CRK & Associates, Chartered Accountants (Firm Regn Number: 010004S), as Internal Auditors of the Company for the year 2026-2027.
b.	date of appointment/ reappointment/cessation (as applicable) & term of appointment/ reappointment ;	The Board at its meeting held on May 29, 2026, approved the appointment of M/s. CRK & Associates, Chartered Accountants (Membership number: 010004S), a Partnership firm as Internal Auditors, for the financial year 2026-2027.
c.	brief profile (in case of appointment);	M/s. CRK & Associates is a firm of Chartered Accountants with about 40 years of experience in audit, taxation, and various other services and the firm has its presence in the 5 major cities in india. The firm has 7 partners and a team of Twenty five experts, paid employees and article assistants. CA. C. Rajendra Kumar (CRK), Senior Partner, is a regular Honorary Faculty member on Forensic Audit to the officials of Central Economic Intelligence Bureau (CEIB), under the Ministry of Finance, Comprising of Officials from Ministry of Homes Affairs (MHA), Research & Analysis (RAW), Intelligence Bureau (IB), Enforcement Directorate (ED), and Direct & Indirect Taxes in SBI Staff & Training College Hyderabad.
d.	disclosure of relationships between directors (in case of appointment of a director)	Not applicable



SIGACHI LABORATORIES LIMITED

Corporate Office: 411, Raghava Ratna Towers,
Chirag Ali Lane, Hyderabad - 500 001, Telangana (INDIA)
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in
GSTIN: 36AACCS8220M1Z4 CIN: L24230TG1994PLC018786

Annexure-II

The Disclosure required under Regulation 30 of the SEBI Listing Regulations, read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024:

Proposal for Purchase of Plot Nos.20, 21 and 22, admeasuring area 167.00 Square Yards each situated in the HMDA approved layout named "HILL SIDE" at Maheshwaram Revenue Village and Gram Panchayat, Maheshwaram Mandal, Ranga Reddy District, Telangana.

Details of Counterparties (including name and relationship with the listed entity)	Name: AMAZE INFRA DEVELOPERS Relationship: No relationship of our company with promoter/promoter group/group companies/LLP's/Firms.
Purpose of entering into the agreement/sale deed.	To purchase the three plots for investment purpose.
Shareholding, if any, in the entity with whom the agreement is executed	No shareholding/partnership in the entity/individual with whom the sale deed is proposed to be executed.
Significant terms of the agreement (in brief)	Address of Property: Plot Nos.20, 21 and 22, admeasuring area 167 Square Yards each situated in the HMDA approved layout named "HILL SIDE" at Maheshwaram Revenue Village and Gram Panchayat, Maheshwaram Mandal, Ranga Reddy District, Telangana, India. Purchase consideration: Not exceeding Rs. 15 lakhs for each plot plus applicable stamp duty and Registration charges. Source of funds: Internal Accruals.
Extent and the nature of impact on management or control of the listed entity	Not Applicable
Whether the said parties are related to promoter/promoter group/group companies in any manner. If yes, nature of relationship;	No promoter/promoter group/group companies in any manner are a related party.
Whether the transaction would fall within the related party transactions? If yes, whether the same is done at "arm's length"	Not applicable



SIGACHI LABORATORIES LIMITED

Corporate Office: 4th Raghava Ratna Towers,
Chirag Ali Lane, Hyderabad - 500 001, Telangana (INDIA)
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in
GSTIN: 36AACCS8220M1Z4 CIN: L24230TG1994PLC018786

Annexure-III

The Disclosure required under Regulation 30 of the SEBI Listing Regulations, read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024:

Proposal for Purchase of Villa No.35, situated at S. No. 343/1, 343/2 and 338/2, Bidraguppe Village, Attibele Hobli, Anekal Taluk, Bangalore, Bangalore District.

Details of Counterparties (including name and relationship with the listed entity)	Name: 1. Akruti Homes (Bangalore) Private Limited (GPA Holder and Developer) & along with the confirming/consenting party i.e., Mr. Vivek Nadakuditi S/o. Mr. Venkateswara Nadakuditi, Bangalore. Relationship: No relationship of our company with promoter/promoter group/group companies/LLP's/Firms.
Purpose of entering into the agreement/Sale Deed	To purchase the Villa for investment purpose.
Shareholding, if any, in the entity with whom the agreement is executed	No shareholding/partnership in the entity/individual with whom the agreement/sale deed is being executed.
Significant terms of the agreement (in brief)	Address of Property: Villa No.35, situated at S. No. 343/1, 343/2 and 338/2, Bidraguppe Village, Attibele Hobli, Anekal Taluk, Bangalore, Bangalore District, Karnataka, India. - Property Details: Villa admeasuring 2750 sqft., super built-up area comprising Ground, First and Second Floors, car parking spaces and undivided share of 1265 sqft of land. Purchase consideration: Not exceeding Rs.1,20,00,000/- for plus applicable stamp duty and Registration charges, applicable GST, if any and other charges as applicable. Source of funds: Internal Accruals.
Extent and the nature of impact on management or control of the listed entity	Not Applicable
Whether the said parties are related to promoter/promoter group/group companies in any manner. If yes, nature of relationship;	No promoter/promoter group/group companies in any manner are a related party.
Whether the transaction would fall within the related party transactions? If yes, whether the same is done at "arm's length"	Not applicable



SIGACHI LABORATORIES LIMITED

Corporate Office: 4th Floor, Raghava Ratna Towers,

Chirag Ali Lane, Hyderabad - 500 001, Telangana (INDIA)

Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in

GSTIN: 36AACCS8220M1Z4 CIN: L24230TG1994PLC018786

Annexure-IV

The Disclosure required under Regulation 30 of the SEBI Listing Regulations, read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024:

Proposal to Purchase of Mahindra Electric car (XEV 9S – Pack 3) for the company use:

Details of Counterparties (including name and relationship with the listed entity)	Name: 1. Automotive Manufacturers Private Limited, Hyderabad. Relationship: No relationship of our company with promoter/promoter group/group companies/LLP's/Firms.
Purpose of entering into the agreement	For Purchase of Mahindra Electric car (XEV 9S Pack 3) car for official use.
Shareholding, if any, in the entity with whom the agreement is executed	No shareholding/partnership in the entity/individual with whom the aforementioned car is proposed to be purchased.
Significant terms of the agreement (in brief)	Address of Property: Not applicable Purchase consideration: Not exceeding Rs. 32,00,000/-. Source of funds: Internal Accruals.
Extent and the nature of impact on management or control of the listed entity	Not Applicable
Whether the said parties are related to promoter/promoter group/group companies in any manner. If yes, nature of relationship;	No promoter/promoter group/group companies in any manner are a related party.
Whether the transaction would fall within the related party transactions? If yes, whether the same is done at "arm's length"	Not applicable



SIGACHI LABORATORIES LIMITED

Corporate Office: 4th Floor, Raghava Ratna Towers,

Chirag Ali Lane, Hyderabad - 500 001, Telangana (INDIA)

Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in

GSTIN: 36AACCS8220M1Z4 CIN: L24230TG1994PLC018786

Date: 29.05.2026

Head Listing & Compliance
Metropolitan Stock Exchange of India Limited
205(A), 2nd floor, Piramal Agastya Corporate Park,
Kamani Junction, LBS Road,
Kurla (West), Mumbai – 400070

Respected Sirs/Madam,

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding the One Time Loan Settlement (OTS) proposal by Sri. B. Prasad, Director of SUPR Trade Links Private Limited – Reg.

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that our company has sanctioned a loan/ICD of Rs. 5 lakhs to SUPR Trade Links Private Limited, Hyderabad 20 years back and the said company became sick and defaulted in making the loan repayments after making few interest payments initially and our company has written off the entire debt/due amount.

In spite of writing off the debt in the books of account, we have been following up for recovery with the guarantors who are the directors of the company and after many years of persuasions and follow up, one of the guarantor and Director of the company, who along with his family members has mortgaged a flat in a remote place, has come forward to settle for an amount of Rs.6,50,000/- and requested our company that he be released from his guarantorship and release the flat given as security.

All the Directors have also become financially sick and lost heavily by investing in the above said company and the family members who have executed mortgage deed have also created encumbrances on the flat given as security due to their financial problems.

The Board has considered various issues including legal issues and approved the request of Mr. B. Prasad, guarantor and Director of SUPR Trade Links Private Limited who has already paid Rs. Rs.6,50,000/- towards full and final settlement and to release Mr. B. Prasad from his guarantorship and to release the flat given as security for the loan and to cancel the mortgage deed.



SIGACHI LABORATORIES LIMITED

Corporate Office: 411 Raghava Ratna Towers,

Chirag Ali Lane, Hyderabad - 500 001, Telangana (INDIA)

Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in

GSTIN: 36AACCS8220M1Z4 CIN: L24230TG1994PLC018786

Reasons for opting for OTS:

SUPR Trade Links Private Limited (the company) and its directors and guarantors have become financially sick and considering various issues including legal issues, the Board has approved the OTS proposal.

Brief Summary of the OTS:

Our company has already Sanctioned and disbursed the loan/ICD of Rs. 5,00,000/- about 20 years ago and the SUPR Trade Links Private Limited (the company) and its directors and guarantors have become financially sick and our company has also written off the debt long back and considering the receipt of Rs.6,50,000/- from Mr. B. Prasad, the Board has considered and approved the OTS proposal.

Kindly take the same on record and acknowledge.

Thanking you,

Yours faithfully
For Sigachi Laboratories Limited

(Lekha Sai Surapaneni)
Company Secretary